ClinicalTrials.gg
CompletedNCT04235140Updated Sep 19, 2024Results posted

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

A Phase 3 interventional study of LUM/IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 23 sites in 2 countries. Open to participants aged 12 Months and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
12 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
14th of 20
52 · median 66
Started
2020
the only one that year
Phase 3
10 of 20
none open now
Registered
20th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 14th largest by enrollment, is the only one that started in 2020, is one of 10 in phase 3, and was the 20th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This is a Phase 3, multicenter, open-label and roll-over study in participants who are 12 to \<24 months of age at initiation of Lumacaftor/Ivacaftor (LUM/IVA) treatment.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants From Study VX16-809-122 Part B (Study 122)

    • Completed the 24-week Treatment Period and the Safety Follow-up Visit in Study 122B
  • Participants Not From Study 122

    • Subjects will be 1 to less than 2 years of age
    • Homozygous for the F508del mutation (F/F)

Key Exclusion Criteria:

  • Any laboratory abnormalities that would interfere with the study assessments or pose an undue risk for the subject
  • Solid organ or hematological transplantation

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    LUM/IVA

    Participants weighing 7 to less than (\<) 9 kilograms (kg) received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h in the treatment period of 96 weeks. Participants weighing greater than or equal to (\>=)14 kg received LUM 150 mg/IVA 188 mg FDC q12h in the treatment period of 96 weeks.

    Drug: LUM/IVA

Interventions

  • DrugLUM/IVA

    Drug pages: Lumacaftor · Ivacaftor

    LUM/IVA granules for oral administration

    Also known as: lumacaftor/ivacaftor, VX-809/VX-770

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Day 1 up to Week 120

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Week 96

07

Results

Posted Sep 19, 2024

Participant flow

The study was conducted in participants with cystic fibrosis (CF) aged 12 months through less than (\<) 24 months of age at treatment initiation who were homozygous for F508del and participants who completed the 24-week treatment period along with the safety follow-up in study VX16-809-122 (NCT03601637) Part B.

Participant flow — Overall Study
MilestoneLUM/IVA
Started52
Rollover participants39
Lumacaftor (lum)/ ivacaftor (iva)-naïve participants13
Completed38
Not completed14
Withdrew: Adverse event2
Withdrew: Lost to follow-up1
Withdrew: Withdrawal of consent (not due to ae)4
Withdrew: Commercial drug is available for participants7

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Day 1 up to Week 120
Reported as:
Count of participants · Participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsLUM/IVA
Participants with TEAEs52
Participants with SAEs12
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Week 96
Reported as:
Mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)LUM/IVA
Absolute Change in Sweat Chloride (SwCl)-21.0 ± 14.9

Adverse events

Collected over Day 1 to Week 120. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LUM/IVA0/52 (0%)12/52 (23.1%)50/52 (96.2%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventLUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations6/52
ConstipationGastrointestinal disorders2/52
Distal intestinal obstruction syndromeGastrointestinal disorders1/52
Anaphylactic reactionImmune system disorders1/52
COVID-19Infections and infestations1/52
Cellulitis orbitalInfections and infestations1/52
Lower respiratory tract infection viralInfections and infestations1/52
Oral herpesInfections and infestations1/52
Parainfluenzae virus infectionInfections and infestations1/52
SinusitisInfections and infestations1/52
Most frequent other events
Showing 10 of 31
Most frequent other events
EventLUM/IVA
CoughRespiratory, thoracic and mediastinal disorders25/52
Upper respiratory tract infectionInfections and infestations16/52
PyrexiaGeneral disorders15/52
RhinorrhoeaRespiratory, thoracic and mediastinal disorders15/52
ConstipationGastrointestinal disorders14/52
VomitingGastrointestinal disorders14/52
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations14/52
COVID-19Infections and infestations12/52
Ear infectionInfections and infestations12/52
Nasal congestionRespiratory, thoracic and mediastinal disorders9/52

Baseline characteristics

Baseline value was defined as the most recent non-missing measurement (scheduled or unscheduled) collected on or before the first dose of LUM/IVA in this study.

Age, Continuous
Age, Continuous(months)LUM/IVA
Mean18.8 ± 3.32
Sex: Female, Male
Sex: Female, Male(Participants)LUM/IVA
Female24
Male28
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LUM/IVA
Hispanic or Latino1
Not Hispanic or Latino43
Not collected per local regulations8
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LUM/IVA
White40
Black or African American0
Asian0
American Indian or Alaska Native1
Native Hawaiian or Other Pacific Islander0
Not collected per local regulations8
Other1
More than one race2
08

Study locations

23 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Cardinal Glennon Children's Hospital - St. Louis University
    Saint Louis, Missouri 63104, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • NC TraCS Institute - CTRC University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Wake Forest University Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Medical Center of Dallas
    Dallas, Texas 75235, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Utah / Primary Children's Medical Center
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia's Children's Hospital
    Vancouver, Canada
09

References and documents

Publications

  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent research/clinical-trial-data-sharing.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Aug 2023, 41 months.

Results were first posted in Sep 2024, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 41 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Jan 21, 2020
StartActual
Feb 24, 2020
Primary completionActual
Aug 22, 2023
CompletionActual
Aug 22, 2023
Results first posted
Sep 19, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04235140
Responsible party
Sponsor
First posted
Jan 21, 2020
Start date
Feb 24, 2020
Primary completion
Aug 22, 2023
Completion
Aug 22, 2023
Results posted
Sep 19, 2024
Last update
Sep 19, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion